• Advanced Biotherapy Inc., of Los Angeles, said its board decided to restrict its directors from selling common shares until Aug. 31 of next year, unless the stock trades at $1.50 for 14 consecutive trading days prior to that date. The company is developing products based on antibodies to gamma interferon and tumor necrosis factor alpha.

• Alteon Inc., of Ramsey, N.J., reported data from the DIAMOND trial at this week's European Society of Cardiology meeting in Vienna, Austria, showing that treatment with ALT-711 over 16 weeks demonstrated a statistically significant reduction in left ventricular mass and a marked improvement in left ventricular diastolic filling, as well as statistically significant improvements in multiple quality-of-life measurements. Also, patients with Class III heart failure at baseline appeared to benefit the most from ALT-711 treatment. Alteon said the Phase IIa proof-of-concept results supplement positive findings from initial data analyses announced earlier in the year.

• AnorMED Inc., of Vancouver, British Columbia, began enrolling healthy volunteers in a Phase I trial to evaluate the safety of AMD070 for HIV infection. The compound targets the CXCR4 chemokine receptor and is designed to prevent HIV from entering and infecting healthy cells. The study, which is being conducted in collaboration with the U.S. Adult AIDS Clinical Trials Group, will enroll up to 48 volunteers at two U.S. centers. Based on positive data, AnorMED said it would begin a Phase Ib/IIa trial next year in HIV patients. AnorMED, which plans to present the safety data early next year, said it is exploring potential partnering opportunities for use of AMD070 in combination with other HIV therapeutics.

• Aphios Corp., of Woburn, Mass., executed a cooperative agreement with the National Institutes of Health in Bethesda, Md., and the U.S. Army Medical Research Institute of Infectious Diseases in Fort Detrick, Md., to test its library of molecules from unique marine microorganisms for the prevention or treatment of severe acute respiratory syndrome and other coronavirus infections. Aphios said it plans to discover and develop anti-SARS and anticoronavirus drugs.

• Bioenvision Inc., of New York, said its common stock was approved for listing on the American Stock Exchange. On Monday, the stock will begin trading under the symbol "BIV." Friday is the last trading day for Bioenvision's stock on the Over-the-Counter Bulletin Board. Bioenvision is focused on the acquisition, development and distribution of compounds and technologies for treating cancer.

• Cangene Corp., of Toronto, entered a research and development agreement with Acambis plc, of Cambridge, UK, to develop and manufacture a hyperimmune globulin for treating and preventing infection by West Nile virus. The companies will share development and funding for the project. Acambis will provide its investigational ChimeriVax-West Nile vaccine, product-assay technology and testing for efficacy of the product. Cangene will collect plasma and develop and manufacture the product using its established manufacturing process in its Winnipeg facility.

• Charles River Laboratories International Inc., of Wilmington, Mass., lowered its third-quarter revenue growth guidance to a range between 6 percent and 9 percent. The company also forecast earnings per diluted share to range from 39 cents to 41 cents. Earlier guidance forecast revenue growth between 12 percent and 14 percent and earnings from 42 cents to 44 cents. For the full year, revenue is expected to grow between 9 percent and 11 percent, and earnings between $1.58 and $1.63. The company's stock (NYSE:CRL) dropped $4.97 Wednesday, or 13.6 percent, to close at $31.50.

• ComChem Technologies Inc., of Indianapolis, said Cancer Research published the results of preclinical research performed at the Indiana University School of Medicine. The article describes the scientific and clinical rationale identifying PTEN and PI3-kinase as a nonredundant intercept cell signaling switch for cell survival, cell proliferation, angiogenesis and apoptosis. The published results support the concept that controlling PTEN and PI3k with targeted small-molecule drugs could provide significant advantages over several existing therapies for cancer and other diseases, the company said.

• DakoCytomation A/S, of Copenhagen, Denmark, gained exclusive worldwide rights to two antibodies for prostate cancer diagnostics and monitoring from Corixa Corp., of Seattle. More specifically, DakoCytomation will have the exclusive right to develop and commercialize immunohistochemistry diagnostics and the right to develop therapeutic drug-monitoring products related to P504S, a tumor-specific marker, and P501S, specific for prostate tissue. DakoCytomation said resulting diagnostic products would expand its portfolio of tests for managing prostate cancer patients and help physicians link diagnostic assay results to specific therapies and treatment outcomes. Financial terms were not disclosed.

• Diversa Corp., of San Diego, and Givaudan Flavors Corp., of Cincinnati, achieved a milestone in their collaborative agreement to discover and develop enzymes and processes for the production of products for consumer applications. The milestone signifies the development of a biocatalyst that significantly improves the efficient production of a natural flavor ingredient, the companies said. The new process will replace an existing one and is being scaled up for pilot plant trials. Diversa will receive a milestone payment and, upon commercialization, license fees and royalties.

• Fisher Scientific International Inc., of Hampton, N.H., acquired 93.6 percent of Perbio Science AB, of Helinsborg, Sweden, a $250 million manufacturer and supplier of technologies, products and services to the life science and biotechnology industries. Fisher's paid SEK155 (US$18.41) per share and SEK106 per warrant. Remaining shareholders have until Sept. 19 to accept the offer. Fisher, which expects the transaction to be 10 to 15 cents accretive to 2004 diluted earnings per share that are expected to range from $2.65 to $2.80, also filed a universal shelf registration statement with the SEC to issue up to $750 million of debt and equity securities. The company is maintaining its 2003 earnings guidance, excluding one-time costs related to the transaction, of $2.20 to $2.30 per share, and revenue growth of 6.5 percent to 8.5 percent.

• GTC Biotherapeutics Inc., of Framingham, Mass., reduced its total headcount by about 13 percent as part of a restructuring plan to support its development toward product commercialization. Reductions are occurring primarily in the areas of farm operations, molecular biology and administration, moves GTC said would allow it to expand resources to support commercialization without adjusting financial projections.

• Icagen Inc., of Research Triangle Park, N.C., completed enrollment in its Phase II trial of ICA-17043 for the treatment of sickle cell anemia. Results from the 90-patient, double-blind, placebo-controlled, parallel-group study are expected in the first quarter of 2004. A variety of laboratory and clinical endpoints are being evaluated, including changes in certain hematologic parameters and several measures of pain.

• Ingenium Pharmaceuticals AG, of Munich, Germany, reported the publication in the journal Human Molecular Genetics of the first mouse model for cystinuria Type I, a disease commonly known as kidney stones. The mouse mimics the clinical manifestations of the human disease and represents a model for researching therapeutic approaches. Separately, Ingenium and University Hospital Mannheim in Germany entered an outlicense agreement under which the department of urology will access the Ingenotypes mouse model.

• Octagen Corp., of Bala Cynwyd, Pa., and Ipsen Group, of Paris, began a Phase I trial of OBI-1, their recombinant porcine coagulation Factor VIII for hemophilia A inhibitor patients. The study, which will be conducted at up to 20 U.S. and UK sites, is designed to compare the safety and pharmacokinetics of single infusions of genetically engineered OBI-1 and the commercially available porcine Factor VIII called Hyate:C, a product derived from pig plasma and sold by Ipsen.

• Peninsula Pharmaceuticals Inc., of Alameda, Calif. reported the early completion of patient recruitment in its Phase II trial of doripenem, also known as S-4661. Begun earlier this year, the global study is investigating the broad-spectrum carbapenem antibiotic in hospitalized patients with complicated urinary tract infections including pyelonephritis. Peninsula said it would report results later this year.

• Quorex Pharmaceuticals Inc., of Carlsbad, Calif., entered a collaborative agreement with IDEC Pharmaceutical Corp., of San Diego. The parties will use Quorex's Protein Vision bioinformatics platform to identify genes encoding proteins for use as therapeutic targets to treat cancers or inflammatory disorders. Financial terms include undisclosed up-front and research payments.

• ScinoPharm, of the Tainan Science Park in Taiwan, was created as a joint venture between the Taiwanese government and the private sector to develop custom drugs and active pharmaceutical ingredients. The company is part of a broader government initiative to attract biotech sector growth in the region - Taiwan is offering five-year tax exemptions for biotech companies as well as 20 percent tax rebates for investors in approved biotech ventures.

• Sequenom Inc., of San Diego, said it developed a new method for increased multiplexing using its MassARRAY system that allows customers to analyze up to 15 single nucleotide polymorphisms in an individual reaction using existing MassARRAY hardware and software components. Also, the assay design software supports the automated design of multiplexed SNP assays without the need for optimization or validation.

• Sucampo Pharmaceuticals Inc., of Bethesda, Md., appointed Myra Patchen its CEO as company co-founder Ryuji Ueno stepped aside to devote his attention to its research program. Ueno will continue as executive chair and CEO emeritus. Patchen had been the chief operating officer at Sucampo, which has a pipeline of potential products for gastrointestinal, liver and ophthalmic diseases, therapies derived from Ueno's discovery of a new class of bioactive functional fatty acids and development of an entirely new class of compounds.

• Telik Inc., of Palo Alto, Calif., reported that the FDA granted fast-track designation for Telcyta for third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Telcyta is a small-molecule prodrug that is activated by GST P1-1, an enzyme present in higher levels in many human cancers than in normal tissues. Upon activation, apoptosis is initiated.

• ViroLogic Inc., of South San Francisco, was awarded a grant from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health in Bethesda, Md., to develop a hepatitis C virus drug susceptibility assay. The project will focus on the development of rapid and sensitive assays to evaluate the susceptibility of HCV to investigational drugs that inhibit viral polymerase and protease.

No Comments